MyFinsight
Home
Blog
About
Cash and cash
equivalents
$115,981K
(589.30%↑ Y/Y)
Prepaid expenses and
other current assets
$7,430K
(181.76%↑ Y/Y)
Total current assets
$123,411K
(230.46%↑ Y/Y)
Property and equipment,
net
$506K
(-11.69%↓ Y/Y)
Other assets
$78K
(-99.30%↓ Y/Y)
Total assets
$123,995K
(5.79%↑ Y/Y)
Accumulated deficit
-$500,027K
(-22.69%↓ Y/Y)
Total liabilities,
mezzanine equity, and...
$123,995K
(5.79%↑ Y/Y)
Total stockholders'
equity (deficit)
-$35,324K
(-400.99%↓ Y/Y)
Additional paid in capital
$460,447K
(11.47%↑ Y/Y)
Accumulated other
comprehensive income
$4,255K
(-30.88%↓ Y/Y)
Common stock, 0.001 par
value, 250,000,000...
$1K
(-98.11%↓ Y/Y)
Series c preferred
stock, 0.001 par value,...
$143,811K
Total liabilities
$15,508K
(-85.30%↓ Y/Y)
Total current
liabilities
$8,500K
(13.83%↑ Y/Y)
Warrant liabilities
$6,292K
(-58.45%↓ Y/Y)
Other long-term
liabilities
$716K
(-3.89%↓ Y/Y)
Accounts payable
$4,636K
(163.56%↑ Y/Y)
Accrued expenses and
other current...
$3,864K
(-32.31%↓ Y/Y)
Back
Back
Balance Sheet
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)
source: myfinsight.com